Main Article Content
Background: Angiohemophilia (VWD) is a common human inherited disease where the parent carrying the gene may or may not be symptomatic. VWD is an illness of the blood that does not coagulate correctly. Blood contains numerous proteins to stop the bleeding of the body. Von Willebrand factor VWF is one of these proteins.
Aim: Current study was planned to classify the prevalence of VWD between 2014 and 2019 in Nineveh province.
Materials and Methods: The study included 829 patients, 365 of which were carriers of one or more hemophilia factors deficiency. Special Staco kit was used for detecting VWF.
Results: Thirty out of 365 patients were diagnosed with VWD. The association between VWD and other associated variables is not significant. An acceptable value was found between age and blood type.
Conclusion: The origins of families that hold the disease mutant gene must be tracked, births taken and infection mitigation techniques used in these families established. Do not neglect the value of the sort of blood that affects the VWD directly.
Budde U, Pieconka A, Will K, Schneppenheim R. Laboratory testing for von Willebrand disease: Contribution of multimer analysis to diagnosis and classification. Semin Thromb Haemost. 2006;32:514-21.
Favaloro EJ. Collagen binding assay for von Willebrand factor (VWF: CBA): Detection of von Willebrand disease (VWD) and the discrimination of VWD subtypes, depends on collagen source. Thromb Haemost. 2000;83:127-35.
Bharati K, Prashanth U. Von willebrand disease: An overview. Ind J Pharma Sci. 2011;1:7-17.
Bowman M, Mundell G, Grabell J, Hopman WM, Rapson D, Lillicrap D, James P. Generation and validation of the condensed MCMDM-1VWD bleeding questionnaire for von willebrand disease. J Thromb Haemost; 2008.
Archer M, Forbes W, and Brugnara, C. Knowledge of blood group decreases von willebrand factor panel testing in children. Hema Sphere. 2017;1(1):e3.
Soracha W, Jamie O, James O’D. The relationship between ABO blood group, von Willebrand factor and primary hemostasis. Blood. 2020;136(25):2864–2874.
Liui X, Chen X, Yang J, and Guo R. Association of ABO blood groups with von Willebrand factor, factor VIII and ADAMTS 13 in patients with lung cancer. Onco Let. 2017;14:3787-3794.
Sharma R, Haberichter SL. New advances in the diagnosis of von Willebrand disease. Hematology Am Soc Hematol Educ Program. 2019;6(1):596-600.
Franchini M, Capra F, Targher G, Montagnana M, Lippi G. Relationship between ABO blood group and von Willebrand factor levels: From biology to clinical implications. Thromb J. 2007;5(14).
Leebeek F, Chapman M, Ploder B, Sytkowski A, Novack A, Ewenstein B. Treatment of gastrointestinal bleeding episodes with recombinant Von Willebrand Factor (rVWF) in patients with severe von Willebrand disease (VWD): Sub-analysis from pivotal phase III on-demand study. Res Pract Thromb Haemost. 2017;1(1): 880.
Seaman C, Ragni M. The association of aging with von Willebrand factor levels and bleeding risk in type 1 von willebrand disease. Clin App Thro Hemo. 2018;24(3): 434-438.
Mannucci PM. New therapies for von Willebrand disease. Hematology Am Soc Hematol Educ Program. 2019;3(21):590-595.
Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand’s disease. Blood. 1987;69(2):454-9.
Werner EJ, Broxson EH, Tucker EL, et al. Prevalence of von Willebrand disease in children: A multiethnic study. J Pediatr. 1993;123(6):893-8.
Ragni MV, FA Bontempo, C Hassett. Von Willebrand disease and bleeding in women. Hemophilia. 1999;5:313-317.
Ziv O, Ragni MV. Bleeding manifestations in males with von Willebrand disease. Hemophilia. 2004;10:162-8.
Borghi M, Guglielmini G, Mezzasoma A, Falcinelli E, Bury L, Malvestiti M, et al. Increase of von Willebrand factor with aging in type 1 von Willebrand disease: Fact or fiction? Haematologica. 2017; 102 (11):e431-e434.
Lee CA, Chi C, Pavord SR, Bolton-Maggs PH, Pollard D, Hinchcliffe-Wood A, et al. The obstetric and gynaecological management of women with inherited bleeding disorders—review with guidelines produced by a taskforce of UK Haemophilia Centre Doctors’ Organization. Haemophilia. 2006;12:301-36.
Sanders Y, Giezenaar M, Laros-van B, Meijer G, van der Bom J, Cnosse M, et al. von Willebrand disease and aging: An evolving phenotype. J Thromb Haemost. 2014;12(7):1066-75.
Pollak E, Nagalla S. At what age do symptoms of von Willebrand disease (vWD) first appear? Medscape. 2021;21.
Favaloro E, Soltani S, McDonald J, Grezchnik E, Easton L, and Favaloro J. Reassessment of ABO blood group, sex, age on laboratory parameters used to diagnose von Willebrand Disorder. Am J Clin Pathol. 2005;124:910-917.
Orstavik KH, Magnus P, Reisner H, Berg K, Graham JB, Nance W. Factor VIII and factor IX in a twin population: Evidence for a major effect of ABO locus on factor VIII level. Am J Hum Genet. 1985;37:89- 10.
Miller CH, Haff E, Platt SJ, Rawlins P, Drews CD, Dilley AB, Evatt B. Measurement of von Willebrand factor activity: Relative effects of ABO blood type and race. J Thromb Haemost. 2003;1: 2191-2197.
Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR: Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet. 1995;345:152-155.